Acumen reports $306M cash, runway into H1 2027; plans Phase 2-only ALTITUDE-AD study

Acumen Pharmaceuticals, Inc.

Cash, cash equivalents and marketable securities ~$306M as of Dec 31, 2023 (preliminary, unaudited).
Company expects cash to fund operations into first half of 2027.
Anticipates amending ALTITUDE-AD Phase 2/3 protocol to a standalone Phase 2 study.
Updated corporate presentation posted on investor website on March 19, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.